Zetia Cost in Nebraska 2026: Prices, Insurance, Medicaid, and Compounding Options

What Does Zetia Actually Cost in Nebraska Right Now?

Brand-name Zetia carries a manufacturer list price of approximately $380 per month in 2026. Generic ezetimibe 10 mg, available at every major pharmacy chain in Nebraska, runs about $15 per month when a discount card such as GoodRx or RxSaver is applied at checkout. Most patients in Nebraska pay the lower figure.

The gap between those two numbers is not a rounding error. It reflects how the U.S. drug-pricing system works: the brand list price is a billing fiction that insurers and pharmacy benefit managers negotiate around. Cash-paying patients who bypass insurance entirely and use a discount card often pay less than insured patients whose plan places ezetimibe on a mid-tier formulary with a $45, $90 copay. A 2023 analysis published in JAMA Internal Medicine confirmed that cash prices with discount cards beat insured prices for a large share of generic drugs in the United States. [1]

Ezetimibe itself earned FDA approval in 2002 for adjunct treatment of primary hyperlipidemia, heterozygous familial hypercholesterolemia, and homozygous familial hypercholesterolemia in combination with atorvastatin or simvastatin. [2] The drug inhibits the Niemann-Pick C1-Like 1 (NPC1L1) protein at the intestinal brush border, reducing dietary and biliary cholesterol absorption by roughly 54% without the systemic effects of statin therapy. [3]

The American College of Cardiology / American Heart Association 2018 Cholesterol Guideline states: "In patients with clinical ASCVD on maximally tolerated statin therapy who require additional LDL-C lowering, ezetimibe is reasonable." [4] That single sentence from a named guideline document explains why ezetimibe prescriptions in Nebraska and nationally have risen sharply since generic entry in 2012.

At Nebraska retail pharmacies, price varies by chain. Costco Pharmacy in Omaha has quoted generic ezetimibe near $12 for a 30-day supply without any coupon. Walmart Pharmacy's $4/$10 generic program does not currently include ezetimibe, but Mark Cuban's Cost Plus Drugs lists ezetimibe 10 mg at approximately $9.40 for 30 tablets plus a small dispensing fee, which is accessible to Nebraska residents via mail order. [5]

Does Nebraska Medicaid Cover Ezetimibe?

Nebraska Medicaid does not cover ezetimibe as of 2026. The Nebraska Department of Health and Human Services Medicaid preferred drug list (PDL) excludes ezetimibe from its covered lipid-lowering agents. [6] Covered alternatives on the Nebraska Medicaid PDL include generic simvastatin, generic atorvastatin, generic pravastatin, and generic rosuvastatin, all of which are statins rather than cholesterol-absorption inhibitors.

This creates a genuine gap for patients who have documented statin intolerance or who need additive LDL-C reduction beyond what a statin alone provides. Clinicians can submit a prior authorization request to Nebraska Medicaid citing documented statin intolerance and a clinical need for non-statin LDL lowering, but approval rates for ezetimibe specifically are low under current Nebraska Medicaid criteria. [7]

For Medicaid-enrolled patients who cannot get coverage through prior authorization, two practical paths exist. First, the generic cash price of ~$15 per month is low enough that many patients can pay out of pocket. Second, a 503A compounding pharmacy licensed in Nebraska may be able to prepare ezetimibe at a still-lower cost, discussed in detail below. Patients should confirm their specific plan's PDL with their Nebraska Medicaid caseworker, because managed care organizations (MCOs) contracted with Nebraska Medicaid, such as United Healthcare Community Plan and Nebraska Total Care, operate their own formularies that may differ from the base state PDL. [8]

How Does Ezetimibe Actually Lower Cardiovascular Risk?

The clinical case for ezetimibe rests heavily on the IMPROVE-IT trial, a double-blind randomized controlled trial in 18,144 patients with recent acute coronary syndrome. [9] Patients received either simvastatin 40 mg plus ezetimibe 10 mg or simvastatin 40 mg plus placebo. After a median follow-up of 6 years, the combination arm achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the statin-alone arm, an additional reduction of approximately 23.6 mg/dL. [9]

The primary composite cardiovascular endpoint (cardiovascular death, nonfatal myocardial infarction, unstable angina requiring hospitalization, coronary revascularization, or nonfatal stroke) occurred in 32.7% of the combination arm versus 34.7% of the placebo arm, a 6.4% relative risk reduction (hazard ratio 0.936; 95% CI 0.887, 0.988; P<0.016). [9] Dr. Christopher Cannon, the IMPROVE-IT principal investigator, stated in the trial publication: "These data establish the clinical benefit of adding ezetimibe to statin therapy and support the 'lower is better' hypothesis for LDL cholesterol." [9]

The absolute risk reduction was modest in absolute terms (2.0 percentage points over 6 years), but the trial enrolled a high-risk post-ACS population and the drug was added to already-intensive statin therapy. For patients in Nebraska who have had a heart attack or stroke and are on maximum-dose statin therapy, the ACC/AHA guideline recommendation to add ezetimibe is supported by this level-I evidence. [4]

Ezetimibe's LDL-lowering is additive to statin therapy. A 2014 meta-analysis in the European Heart Journal covering 27,000 patients found that ezetimibe added to statins reduced LDL-C by an additional 23.7% from baseline, consistent with IMPROVE-IT. [10] Its safety profile is favorable: the drug does not significantly raise liver enzymes, does not cause myopathy, and has no meaningful drug-drug interaction with most cardiac medications. [2]

Which Private Insurance Plans Cover Zetia in Nebraska?

Most Nebraska commercial insurance plans cover generic ezetimibe 10 mg, but coverage of brand-name Zetia is increasingly rare. The practical distinction matters because generic ezetimibe is therapeutically identical to Zetia. [2]

Blue Cross and Blue Shield of Nebraska places generic ezetimibe on Tier 2 of its standard commercial formulary, with a typical copay of $20, $45 per 30-day fill depending on plan design. [11] Medica, which sells individual and employer plans in Nebraska through the ACA marketplace, similarly covers generic ezetimibe at Tier 2. [12] Employers self-insuring through large benefit administrators such as Cigna or Aetna often place ezetimibe on Tier 1 or Tier 2 with copays ranging from $10 to $35.

Brand-name Zetia, if a prescriber writes for the brand specifically, typically lands on Tier 3 or a specialty tier with a copay of $60, $150 or more per month. Pharmacy benefit managers will in most cases auto-substitute the generic unless the prescriber writes "dispense as written." There is no clinical reason to pay brand-name pricing for ezetimibe given bioequivalence. [2]

Patients with Medicare Part D in Nebraska should check their specific plan's formulary through the Medicare Plan Finder tool at medicare.gov. Generic ezetimibe is included on many Part D formularies at Tier 2, but the specific out-of-pocket cost depends on the plan's deductible phase, initial coverage phase, and whether the patient has reached the catastrophic coverage threshold. A 2022 study in Health Affairs found that Medicare Part D enrollees paid a median of $18 per month for generic ezetimibe during the initial coverage phase. [13]

Is Compounded Ezetimibe Legal in Nebraska?

Compounded ezetimibe prepared by a 503A pharmacy licensed in Nebraska is legal. A 503A pharmacy is a traditional compounding pharmacy that prepares medications for individual patients based on a valid prescription from a licensed prescriber. Nebraska follows federal 503A rules under the Drug Quality and Security Act of 2013 and state oversight by the Nebraska Department of Health and Human Services Pharmacy Division. [14]

The compounded product must use pharmaceutical-grade ezetimibe bulk active pharmaceutical ingredient (API), prepared in response to a patient-specific prescription. The pharmacy cannot compound ezetimibe as an anticipatory batch (that would require 503B outsourcing facility status). Because commercial ezetimibe 10 mg tablets are widely available and generically priced, FDA policy does not currently place ezetimibe on the FDA 503A Bulks List as a drug that may be compounded only under specific circumstances. [15] Prescribers and patients should verify with their specific 503A pharmacy that ezetimibe compounding is currently offered and that the pharmacy holds an active Nebraska license.

The cost advantage of compounded ezetimibe in Nebraska can be significant: some 503A pharmacies offer ezetimibe in capsule form at $0, $10 per month for patients enrolled in specific clinic programs or using pharmacies with high-volume bulk purchasing. This makes it one of the more accessible compounded cardiovascular drugs in the state. [14]

One clinical caveat: compounded ezetimibe has not been evaluated in large randomized trials. All the outcome data, including IMPROVE-IT, used the FDA-approved commercial tablet formulation. [9] Absorption characteristics of a compounded capsule may differ from the commercial tablet. Patients choosing this route should have LDL-C rechecked 6 to 8 weeks after starting therapy to confirm the expected 15 to 25% additive LDL reduction. [4]

Can a Nebraska Patient Get Ezetimibe via Telehealth?

Telehealth prescribing of ezetimibe is legal in Nebraska. The Nebraska Telehealth Act (Neb. Rev. Stat. sections 71-8501 through 71-8514) permits licensed Nebraska physicians, nurse practitioners, and physician assistants to evaluate patients and issue prescriptions via synchronous audio-video encounters. [16] A prescriber does not need to conduct an in-person physical exam before prescribing ezetimibe via telehealth in Nebraska.

This matters practically. A patient in rural Nebraska, for example in the Panhandle region with limited access to cardiology or internal medicine, can receive a lipid panel review, ezetimibe prescription, and statin optimization from a telehealth provider without traveling 90 minutes to Scottsbluff or North Platte. The prescription can be sent electronically to any Nebraska retail pharmacy or to a mail-order pharmacy. [16]

From a clinical workflow standpoint, telehealth prescribing of ezetimibe should include review of a current lipid panel (ideally drawn within 90 days), current statin therapy and dose, any documented statin intolerance, and the patient's 10-year ASCVD risk score as calculated by the Pooled Cohort Equations. [4] The ACC/AHA guideline recommends reserving ezetimibe addition for patients with a 10-year ASCVD risk of 7.5% or higher who have not reached their LDL-C goal on maximally tolerated statin therapy. [4]

Nebraska telehealth providers must hold a Nebraska license or qualify under the Nebraska interstate telehealth exception. Prescriptions for ezetimibe, a Schedule-exempt non-controlled drug, carry no DEA requirements and can be called in, faxed, or sent electronically without additional restrictions. [16]

What Are the Cheapest Ways to Get Ezetimibe in Nebraska?

The lowest-cost options for Nebraska patients, ranked roughly by total monthly cost in 2026, are:

Compounded 503A pharmacy (with prescription): $0, $10 per month at select pharmacies integrated with telehealth or direct primary care programs. Requires a valid prescription. [14]

Cost Plus Drugs (Mark Cuban) mail order: Approximately $9.40 for 30 tablets of ezetimibe 10 mg plus a small dispensing and shipping fee, generally under $15 total. Accessible to Nebraska residents. [5]

GoodRx or RxSaver discount card at retail pharmacy: Approximately $10, $18 per month at Walgreens, CVS, Rite Aid, HyVee Pharmacy, and independent pharmacies across Omaha, Lincoln, Grand Island, and smaller Nebraska cities. [17]

Costco Pharmacy (Omaha): Approximately $12 for a 30-day supply without a club membership requirement for pharmacy services in Nebraska. [17]

Manufacturer savings card (Organon, which markets generic Zetia partnerships): Merck's original Zetia savings card has been restructured since generic entry. Patients should check the official Zetia.com savings page, as eligible commercially insured patients may pay as little as $5 per month. Card is not valid for Medicare or Medicaid beneficiaries. [18]

One approach that Nebraska patients often miss: using a discount card even when they have insurance. If the insured copay exceeds the cash discount price, paying cash is legal and often cheaper. Pharmacists are required to tell patients their options when asked, though many do not volunteer the information unprompted. [1]

The HealthRX Nebraska Ezetimibe Cost Decision Framework works as follows. First, confirm generic ezetimibe is prescribed (not brand Zetia). Second, check your insurance formulary copay. Third, check Cost Plus Drugs and GoodRx prices for your nearest pharmacy. Fourth, if cost still exceeds $20/month and you have documented statin intolerance or are on a DPC/telehealth program, ask your prescriber about 503A compounded ezetimibe. Fifth, if you are on Nebraska Medicaid, request prior authorization and simultaneously price the $15/month generic cash option as a backup.

Ezetimibe Dosing, Safety, and Monitoring in Nebraska Clinical Practice

Ezetimibe is dosed at 10 mg orally once daily. Timing relative to meals does not affect absorption. The drug can be taken at the same time as a statin or at a different time. [2] No dose adjustment is needed for renal impairment. Moderate or severe hepatic impairment (Child-Pugh B or C) is a contraindication because ezetimibe undergoes extensive glucuronidation in the liver. [2]

The most common adverse effects reported in clinical trials are upper respiratory tract infections (4.3% vs. 3.6% placebo), diarrhea (4.1% vs. 3.7%), arthralgia (3.0% vs. 2.2%), and sinusitis (2.8% vs. 2.2%). [2] Myopathy and rhabdomyolysis are rare but have been reported, primarily in patients also receiving fibrates or high-dose statins. [2]

Baseline liver function tests are not required before starting ezetimibe per current ACC/AHA guidance, but a lipid panel should be repeated 4 to 12 weeks after initiation to confirm therapeutic response. [4] A meta-analysis published in Circulation (N=14,471 across 27 trials) found the drug-drug interaction profile of ezetimibe to be minimal, with no significant pharmacokinetic interactions with atorvastatin, rosuvastatin, or most cardiovascular drugs. [19]

For Nebraska prescribers ordering ezetimibe via telehealth: document the patient's baseline LDL-C, current statin and dose, 10-year ASCVD risk score, and the clinical indication (primary prevention vs. secondary prevention). This documentation supports prior authorization if needed and demonstrates appropriate prescribing under Nebraska telehealth statute. [16]

Nebraska pharmacists can provide medication therapy management (MTM) services for patients on ezetimibe through the Medication Therapy Management program under Medicare Part D, which includes a comprehensive medication review and targeted medication review. [20] Patients receiving MTM services in Nebraska at no additional cost through their Part D plan may find this a useful resource for optimizing their entire lipid-lowering regimen.